Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer Acquires Medivation in $14B Deal

By Meg Snyder | August 22, 2016

Pfizer announced a definitive merger agreement to acquire the cancer drug company Medivation in a deal with a $14 billion-dollar price tag—adding Medivation’s oncology portfolio to Pfizer’s offerings. 

Paying $81.50 per Medivation share (a 21 percent premium to Friday’s closing stock price), Pfizer’s purchase comes at the end of months of bidding for Medivation. According to reports, Pfizer wasn’t the only company interested in acquiring Medivation—Sanofi, Merck, Celgene, and Gilead Sciences also expressed interest. Three months ago, Medivation rejected a “$9.3 billion takeover bid from the French drugmaker Sanofi, saying that offer, worth $52.50 per share, undervalued the company,” AP said. 

Medivation’s late-stage prostate cancer treatment, Xtandi, generates about $2 billion in yearly sales, with the potential to more than double. It is indicated for men with prostate cancer who no longer respond to medical or surgical treatment. Specifically, it is “an androgen receptor inhibitor indicated for the treatment of patients with metastic castration-resistant prostate cancer,” according to the full prescribing information. Xtandi is jointly marketed by Medivation and Astellas. 

Medivation is also developing talazoparib, which—some analysts project—has the potential to accrue several billion each year in sales. 

According to The Wall Street Journal:

Pfizer said the deal would add 5 cents to earnings in the first full year after closing and isn’t expected to affect its 2016 financial guidance. Pfizer said it plans to finance the transaction with its cash holdings.

If the deal isn’t completed, Medivation could pay Pfizer a $510 million termination fee, according to a regulatory filing.

Medivation, one of the few “independent biotechs left with a cancer treatment that is already approved and selling well,” has a promising pipeline of cancer drugs in late-stage clinical development, including treatments for breast cancer and lymphoma. 

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!  


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE